The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorman Broadb Regulatory News (NBB)

Share Price Information for Norman Broadb (NBB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 8.50
Ask: 10.00
Change: -0.50 (-5.13%)
Spread: 1.50 (17.647%)
Open: 9.25
High: 9.50
Low: 9.25
Prev. Close: 9.75
NBB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

24 Jan 2020 07:00

RNS Number : 7886A
Norman Broadbent PLC
24 January 2020
 

Norman Broadbent plc

("Norman Broadbent", "NBB" or the "Group")

FY2019 Trading Update

Norman Broadbent (AIM: NBB) - a leading London listed Professional Services firm offering a diversified portfolio of integrated Leadership Acquisition & Advisory Services (Board & Leadership Search, Senior Interim Management, Research & Insight, Leadership Consulting & Assessment, and executive-level Talent Solutions) - provides the following unaudited trading update relating to the 12 months ended 31/12/2019.

The Board is pleased to report that following the progress made in the first six months of 2019, the underlying growth in revenue and improvement in operating results has continued into the second half of the year. This has seen the company return to profitability for the full year to 31 December 2019. A turnaround and transformation of this scale is pleasing, particularly when many in our industry are referencing lower than anticipated UK trading and significant disruption in H2 2019 due to political and Brexit uncertainty.

Highlights:

o Group Revenues increased YoY by 22% to £11.5m (2018 £9.4m)

o Group Net Fee Income increased YoY by 15% to £7.6m (2018 £6.6m)

o Group returns to full year profit for 2019

o Good H2 results bettering H1

The table below represents the progress made by the Group since 2017.

2017 2018 2019

Group revenue (£m) 6.5 9.4 11.5

Net fee income (£m) 5.0 6.6 7.6

The Group anticipates releasing the full results for FY2019 in early April.

Mike Brennan Group CEO of Norman Broadbent, commented

"The continued growth in revenue and our return to full-year profitability after several years of losses is an extremely important milestone for Norman Broadbent. As we move forward into 2020 these results further evidence that our strategy of building a more diversified, innovative and relevant business is working. Our diversification strategy has created a more balanced Group offering clients a range of consulting, research-related, and impactful Leadership Advisory & Acquisition solutions.

We continue to invest in high-quality Talent. In particular we are pleased to announce the opening of a new North-West office in March 2019. Our North-West team are already hired, fully operational, and starting to contribute.

In London we will shortly be relocating to new, larger offices in SW1 enabling us to scale further.

On achieving this important profit milestone, I would like to again thank my colleagues for their hard work, innovation and commitment, our clients for placing their continued trust in us, and our supportive shareholders."

For further information please contact:

Norman Broadbent plc / Mike Brennan 020 7484 0000

WH Ireland Limited / Adrian Hadden 020 7220 1666

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFLFVDLTIVFII
Date   Source Headline
25th Apr 20247:00 amRNSQ1 2024 Trading Update
24th Apr 20247:00 amRNSSmall Cap Awards nomination
15th Apr 20243:18 pmRNSNotification of major holdings
8th Apr 202412:11 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20244:01 pmRNSNotification of major holdings
28th Mar 20247:00 amRNSPosting of ARA & Notice of AGM
27th Mar 20247:00 amRNSFinal Results
26th Mar 20244:07 pmRNSNotification of major holdings
20th Mar 20241:36 pmRNSNotice of Results & Investor Presentation
18th Mar 20244:33 pmRNSNotification of major holdings
18th Mar 20244:04 pmRNSNotification of major holdings
12th Mar 20243:33 pmRNSAIM Rule 17 Schedule Two (g) Update
22nd Jan 20245:32 pmRNSNotification of Major Holdings
16th Jan 20247:00 amRNSTrading Update
21st Nov 202310:06 amRNSNotification of Major Holdings
20th Nov 202310:45 amRNSDirector/PDMR shareholding
15th Nov 20239:54 amRNSNotification of Major Holdings
15th Nov 20239:43 amRNSNotification of Major Holdings
10th Nov 20237:00 amRNSDirector/PCA Dealing
9th Nov 20232:25 pmRNSDirector/PDMR Shareholding
2nd Nov 20238:43 amRNSConversion Of Outstanding Convertible Loan Notes
12th Oct 20237:00 amRNSQ3 2023 Trading Update
10th Oct 202311:03 amRNSNotification of Major Holdings
9th Oct 20237:00 amRNSSurrender and Granting of Options
28th Jul 20237:00 amRNSGrant of Options
24th Jul 20237:00 amRNSInterim Results
11th Jul 20237:00 amRNSH1 2023 Trading Update
30th Jun 20237:00 amRNSSAYE Option Plan & Director Holding
29th Jun 20234:28 pmRNSResult of AGM
5th Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
1st Jun 20237:00 amRNSDirectorate changes
31st May 20237:00 amRNSFinal Results
22nd May 20237:00 amRNSQ1 2023 Trading Update
19th May 202312:55 pmRNSPartial Repayment of Convertible Loan Note
24th Jan 20237:00 amRNSTrading Update
10th Jan 20237:00 amRNSDirectorate Change
17th Nov 20224:42 pmRNSTR-1: Notification of major holdings
14th Nov 20227:00 amRNSIssue of Equity
1st Nov 20227:00 amRNSUpdate and Change of Board role
10th Oct 20225:30 pmRNSTR-1: Notification of major holdings
31st Aug 20227:00 amRNSDirector Share Purchase
23rd Aug 20227:00 amRNSDirectorate Change
16th Aug 20227:00 amRNSInterim Results
29th Jul 20227:00 amRNSChange of Adviser
20th Jul 20224:08 pmRNSDirector/PDMR Dealing
11th Jul 20227:00 amRNSTrading Update
29th Jun 20223:15 pmRNSDirector/PDMR Shareholding
23rd Jun 202212:14 pmRNSResult of AGM
7th Jun 20228:59 amRNSHolding(s) in Company
25th May 20227:00 amRNSFinal 2021 Results and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.